Dimension Therapeutics Elects Industry Veteran And Finance Officer George Migausky To Its Board Of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dimension Therapeutics, Inc. ("Dimension" or the "Company"), a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced the election of George Migausky to the Company's Board of Directors. Mr. Migausky brings more than 30 years of senior financial management experience with high-growth life science and technology companies. His election to Dimension's Board is effective immediately, and he will chair the newly established audit committee.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.